File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical and basic research advances of traditional Chinese medical on diabetic retinopathy

TitleClinical and basic research advances of traditional Chinese medical on diabetic retinopathy
中醫藥治療糖尿病視網膜病變臨床與基礎研究進展
Authors
KeywordsDiabetic retinopathy (糖尿病視網膜病變)
Traditional Chinese medicine (中藥)
Microangiopathy (微血管病變)
Macular edema (黃斑水腫)
Issue Date2014
PublisherZhongguo Zhong Yi Yan Ke Za Zhi Bian Ji Bu (中國中醫眼科雜誌編輯部). The Journal's web site is located at http://zgzyykzz.periodicals.net.cn/
Citation
Journal Of Traditional Chinese Ophthalmology, 2014, v. 24 n. 3, p. 90-95 How to Cite?
中國中醫眼科雜誌, 2014, v. 24 n. 3, p. 90-95 How to Cite?
Abstract糖尿病視網膜病變(DR)是以微血管病變為主的糖尿病嚴重并發癥之一。中藥治療DR從'消瘀'入手,不同階段分別配以清熱、涼血、補益等治法,通過下調高血糖所激活的蛋白激酶C(Protein Kinase C,PKC)、多元醇、非酶糖基化(AGEs)、聚腺苷酸二磷酸核糖聚合酶(PARP)和氨基己糖等途徑活性,減少活性氧簇的產生,抑制氧化應激、細胞凋亡、炎癥、血管新生等組成的瀑布層疊效應事件,在改善視力、視野,延緩或抑制血管新生,加速黃斑水腫消除,改善視網膜微循環等多方面具有顯著綜合優勢。本文將從臨床、基礎研究兩方面將近年中藥治療DR進展綜述如下。 Diabetic retinopathy(DR) is one of the severest complications of diabetes,whose pathology is microvascular dysfunction mostly.Traditional Chinese medicine(TCM) focused on vanishing blood stasis,and combined with clearing heat,cooling blood,nourishing and so on during different stages of DR.The drugs decreased reactive oxygen species(ROS) inducing,inhibited oxidative stress,apoptosis,inflammation,angiogenesis to ameliorate vision,macular edema,microvascular,and to inhibit new vessels appearing,via down-regulating advanced glycation end products(AGEs),polyol,poly polymerase(PARP),protein kinase C(PKC) and hexosamine pathways hyperglycemia induced.In this study,TCM on clinical and basic research on DR was reviewed.
Persistent Identifierhttp://hdl.handle.net/10722/233006
ISSN

 

DC FieldValueLanguage
dc.contributor.authorWang, L-
dc.contributor.authorWang, N-
dc.contributor.authorFeng, Y-
dc.contributor.authorZhang, YJ-
dc.date.accessioned2016-09-20T05:33:55Z-
dc.date.available2016-09-20T05:33:55Z-
dc.date.issued2014-
dc.identifier.citationJournal Of Traditional Chinese Ophthalmology, 2014, v. 24 n. 3, p. 90-95-
dc.identifier.citation中國中醫眼科雜誌, 2014, v. 24 n. 3, p. 90-95-
dc.identifier.issn1002-4379-
dc.identifier.urihttp://hdl.handle.net/10722/233006-
dc.description.abstract糖尿病視網膜病變(DR)是以微血管病變為主的糖尿病嚴重并發癥之一。中藥治療DR從'消瘀'入手,不同階段分別配以清熱、涼血、補益等治法,通過下調高血糖所激活的蛋白激酶C(Protein Kinase C,PKC)、多元醇、非酶糖基化(AGEs)、聚腺苷酸二磷酸核糖聚合酶(PARP)和氨基己糖等途徑活性,減少活性氧簇的產生,抑制氧化應激、細胞凋亡、炎癥、血管新生等組成的瀑布層疊效應事件,在改善視力、視野,延緩或抑制血管新生,加速黃斑水腫消除,改善視網膜微循環等多方面具有顯著綜合優勢。本文將從臨床、基礎研究兩方面將近年中藥治療DR進展綜述如下。 Diabetic retinopathy(DR) is one of the severest complications of diabetes,whose pathology is microvascular dysfunction mostly.Traditional Chinese medicine(TCM) focused on vanishing blood stasis,and combined with clearing heat,cooling blood,nourishing and so on during different stages of DR.The drugs decreased reactive oxygen species(ROS) inducing,inhibited oxidative stress,apoptosis,inflammation,angiogenesis to ameliorate vision,macular edema,microvascular,and to inhibit new vessels appearing,via down-regulating advanced glycation end products(AGEs),polyol,poly polymerase(PARP),protein kinase C(PKC) and hexosamine pathways hyperglycemia induced.In this study,TCM on clinical and basic research on DR was reviewed.-
dc.languagechi-
dc.publisherZhongguo Zhong Yi Yan Ke Za Zhi Bian Ji Bu (中國中醫眼科雜誌編輯部). The Journal's web site is located at http://zgzyykzz.periodicals.net.cn/-
dc.relation.ispartofJournal Of Traditional Chinese Ophthalmology-
dc.relation.ispartof中國中醫眼科雜誌-
dc.subjectDiabetic retinopathy (糖尿病視網膜病變)-
dc.subjectTraditional Chinese medicine (中藥)-
dc.subjectMicroangiopathy (微血管病變)-
dc.subjectMacular edema (黃斑水腫)-
dc.titleClinical and basic research advances of traditional Chinese medical on diabetic retinopathy-
dc.title中醫藥治療糖尿病視網膜病變臨床與基礎研究進展-
dc.typeArticle-
dc.identifier.emailWang, N: ckwang@hku.hk-
dc.identifier.emailFeng, Y: yfeng@hku.hk-
dc.identifier.authorityWang, N=rp02075-
dc.identifier.authorityFeng, Y=rp00466-
dc.identifier.doi10.13444/j.cnki.zgzyykzz.003299-
dc.identifier.hkuros266594-
dc.identifier.volume24-
dc.identifier.issue3-
dc.identifier.spage90-
dc.identifier.epage95-
dc.publisher.placeBeijing (北京)-
dc.customcontrol.immutablecsl 161205-
dc.identifier.issnl1002-4379-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats